Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective for this study is to establish the superiority of GSK1120212 over chemotherapy with respect to progression-free survival for subjects with advanced/metastatic BRAF V600E mutation-positive melanoma without a history of prior brain metastases.
Critère d'inclusion
- Advanced or metastatic BRAF V600E/K mutation-positive melanoma